Literature DB >> 17251560

Dual effect of APOBEC3G on Hepatitis B virus.

Chiemi Noguchi1, Nobuhiko Hiraga, Nami Mori, Masataka Tsuge, Michio Imamura, Shoichi Takahashi, Yoshifumi Fujimoto, Hidenori Ochi, Hiromi Abe, Toshiro Maekawa, Hiromi Yatsuji, Kotaro Shirakawa, Akifumi Takaori-Kondo, Kazuaki Chayama.   

Abstract

G to A hypermutation of Hepatitis B virus (HBV) and retroviruses appears as a result of deamination activities of host APOBEC proteins and is thought to play a role in innate antiviral immunity. Alpha and gamma interferons (IFN-alpha and -gamma) have been reported to upregulate the transcription of APOBEC3G, which is known to reduce the replication of HBV. We investigated the number of hypermutated genomes under various conditions by developing a quantitative measurement. The level of hypermutated HBV in a HepG2 cell line, which is semi-permissive for retrovirus, was 2.3 in 10(4) HBV genomes, but only 0.5 in 10(4) in permissive Huh7 cells. The level of APOBEC3G mRNA was about ten times greater in HepG2 cells than in Huh7 cells. Treatment of HepG2 cells with either IFN-alpha or -gamma increased the transcription of APOBEC3G and hypermutation of HBV. These mRNAs and hypermutation of HBV genomes were induced more prominently by IFN-gamma than by IFN-alpha. Both IFNs decreased the number of replicative intermediate of HBV. Overexpression of APOBEC3G reduced the number of replicative intermediate of HBV and increased hypermutated genomes 334 times, reaching 968 in 10(4) genomes. Deamination-inactive APOBEC3G did not induce hypermutation, but reduced the virus equally. Our results suggest that APOBEC3G, upregulated by IFNs, has a dual effect on HBV: induction of hypermutation and reduction of virus synthesis. The effect of hypermutation on infectivity should be investigated further.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251560     DOI: 10.1099/vir.0.82319-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  31 in total

Review 1.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

Review 2.  Host restriction factors blocking retroviral replication.

Authors:  Daniel Wolf; Stephen P Goff
Journal:  Annu Rev Genet       Date:  2008       Impact factor: 16.830

Review 3.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

4.  Correlation of APOBEC3G expression with liver function indexes of patients with chronic hepatitis B and comparison in chronic hepatitis B, liver cirrhosis and liver cancer.

Authors:  Lina Ni; Chuanbao Li; Yingbo Li
Journal:  Oncol Lett       Date:  2020-01-24       Impact factor: 2.967

5.  Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.

Authors:  Takuro Uchida; Michio Imamura; C Nelson Hayes; Nobuhiko Hiraga; Hiromi Kan; Masataka Tsuge; Hiromi Abe-Chayama; Yizhou Zhang; Grace Naswa Makokha; Hiroshi Aikata; Daiki Miki; Hidenori Ochi; Yuji Ishida; Chise Tateno; Kazuaki Chayama
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolution.

Authors:  Kimberly Schmitt; Kejun Guo; Malinda Algaier; Autumn Ruiz; Fang Cheng; Jianming Qiu; Silke Wissing; Mario L Santiago; Edward B Stephens
Journal:  Virology       Date:  2011-08-25       Impact factor: 3.616

Review 7.  Molecular mechanisms underlying occult hepatitis B virus infection.

Authors:  Jasmine Samal; Manish Kandpal; Perumal Vivekanandan
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

8.  APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers.

Authors:  S Kondo; K Wakae; N Wakisaka; Y Nakanishi; K Ishikawa; T Komori; M Moriyama-Kita; K Endo; S Murono; Z Wang; K Kitamura; T Nishiyama; K Yamaguchi; S Shigenobu; M Muramatsu; T Yoshizaki
Journal:  Oncogene       Date:  2016-10-03       Impact factor: 9.867

9.  Interferon-alpha induces high expression of APOBEC3G and STAT-1 in vitro and in vivo.

Authors:  Hui Chen; Lu-Wen Wang; Yan-Qing Huang; Zuo-Jiong Gong
Journal:  Int J Mol Sci       Date:  2010-09-20       Impact factor: 5.923

10.  Correlation of APOBEC3 in tumor tissues with clinico-pathological features and survival from hepatocellular carcinoma after curative hepatectomy.

Authors:  Zongguo Yang; Yunfei Lu; Qingnian Xu; Liping Zhuang; Bozong Tang; Xiaorong Chen
Journal:  Int J Clin Exp Med       Date:  2015-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.